Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.68 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549250 | 0.92 | MAOB (0.68) | MAOBMAOAHRH3 | |
| SCHEMBL1547975 | 0.90 | MAOB (0.74) | MAOBMAOA | |
| SCHEMBL15344203 | 0.90 | MAOB (0.80) | MAOBMAOA | |
| SCHEMBL29378803 | 0.90 | MAOB (0.57) | MAOBMAOAALOX5HRH3 | |
| SCHEMBL52030 | 0.90 | MAOB (0.57) | MAOBMAOAALOX5HRH3 | |
| SCHEMBL12635690 | 0.90 | MAOB (0.60) | MAOBMAOABCHECYP4F2CYP4A11 | |
| SCHEMBL12182456 | 0.89 | MAOB (0.74) | MAOBMAOAHRH3 | |
| SCHEMBL10204868 | 0.89 | MAOB (0.72) | MAOBMAOALCK | |
| Hydrochloric Acid SCHEMBL23235850 | 0.87 | MAOB (0.70) | MAOBMAOALCK | |
| Hydrochloric Acid SCHEMBL23235829 | 0.87 | MAOB (0.70) | MAOBMAOALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | claimed |
| EP-1910320-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-16 | — | — | EP | claimed |
| WO-2007011065-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-25 | — | — | WO | claimed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | claimed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | claimed |
| CN-115959962-B | Visible light-promoted halogenated alkane hydrodehalogenation method | 中国科学院兰州化学物理研究所 | 2025-05-23 | — | — | CN | disclosed |
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| EP-4252856-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230232827-A1 | METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS RESISTANT TO QoI FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-07-27 | — | — | US | disclosed |
| CN-115959962-A | Visible light promoted halogenated alkane hydrodehalogenation method | 中国科学院兰州化学物理研究所 | 2023-04-14 | — | — | CN | disclosed |
| EP-3380471-B1 | TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | LIEBER INST INC DBA LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2021-09-08 | — | — | EP | disclosed |
| WO-2000052069-A1 | PROCESS FOR PRODUCING POLYETHYLENE | EASTMAN CHEMICAL COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000052068-A1 | PROCESS FOR PRODUCING POLYETHYLENE | EASTMAN CHEMICAL COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| US-6020379-A | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-5691315-A | CARDIOVASCULAR DISORDERS; VASODILATOR; BRONCHODILATOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5470833-A | Vasodilators, bronchodilators | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| US-5444152-A | Vasolidator or bronchodilator | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0664316-A1 | Polycarbonate composition having improved resistance to gamma-ray radiation | TEIJIN LIMITED (JP) | 1995-07-26 | — | — | EP | disclosed |
| US-3954852-A | Indenylacetic acid compounds | MERCK & CO., INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230232827-A1 | METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS RESISTANT TO QoI FUNGICIDES | CYC1, SQOR, MT-CO3 | MAOB 196/4885MAOA 491/4885BCHE 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.